Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
J Virol. 2010 Aug;84(15):7581-91. doi: 10.1128/JVI.00286-10. Epub 2010 May 26.
Human immunodeficiency virus type 1 (HIV-1) controllers maintain viremia at <2,000 RNA copies/ml without antiretroviral therapy. Viruses from controllers with chronic infection were shown to exhibit impaired replication capacities, in part associated with escape mutations from cytotoxic-T-lymphocyte (CTL) responses. In contrast, little is known about viruses during acute/early infection in individuals who subsequently become HIV controllers. Here, we examine the viral replication capacities, HLA types, and virus sequences from 18 HIV-1 controllers identified during primary infection. gag-protease chimeric viruses constructed using the earliest postinfection samples displayed significantly lower replication capacities than isolates from persons who failed to control viremia (P = 0.0003). Protective HLA class I alleles were not enriched in these early HIV controllers, but viral sequencing revealed a significantly higher prevalence of drug resistance mutations associated with impaired viral fitness in controllers than in noncontrollers (6/15 [40.0%] versus 10/80 [12.5%], P = 0.018). Moreover, of two HLA-B57-positive (B57(+)) controllers identified, both harbored, at the earliest time point tested, signature escape mutations within Gag that likewise impair viral replication capacity. Only five controllers did not express "protective" alleles or harbor viruses with drug resistance mutations; intriguingly, two of them displayed typical B57 signature mutations (T242N), suggesting the acquisition of attenuated viruses from B57(+) donors. These data indicate that acute/early stage viruses from persons who become controllers have evidence of reduced replication capacity during the initial stages of infection which is likely associated with transmitted or acquired CTL escape mutations or transmitted drug resistance mutations. These data suggest that viral dynamics during acute infection have a major impact on HIV disease outcome.
人类免疫缺陷病毒 1 型(HIV-1)控制器在没有抗逆转录病毒治疗的情况下将病毒血症维持在<2000 个 RNA 拷贝/ml。研究表明,慢性感染的控制器中的病毒复制能力受损,部分原因是与细胞毒性 T 淋巴细胞(CTL)反应的逃逸突变有关。相比之下,对于随后成为 HIV 控制器的个体在急性/早期感染期间的病毒知之甚少。在这里,我们检查了 18 名在原发性感染期间被鉴定为 HIV 控制器的个体的病毒复制能力、HLA 类型和病毒序列。使用最早的感染后样本构建的 gag-蛋白酶嵌合病毒显示出比未能控制病毒血症的个体的分离株明显更低的复制能力(P = 0.0003)。在这些早期 HIV 控制器中没有富集保护性 HLA Ⅰ类等位基因,但病毒测序显示,与非控制器相比,与病毒适应性降低相关的耐药突变的发生率在控制器中显著更高(6/15 [40.0%] 对 10/80 [12.5%],P = 0.018)。此外,在鉴定的两名 HLA-B57 阳性(B57(+))控制器中,均在最早检测到的时间点携带 Gag 内同样会损害病毒复制能力的特征性逃逸突变。只有五名控制器不表达“保护性”等位基因或携带耐药突变的病毒;有趣的是,其中两名控制器显示出典型的 B57 特征性突变(T242N),表明从 B57(+)供体中获得了减毒病毒。这些数据表明,成为控制器的个体的急性/早期病毒在感染的初始阶段就具有复制能力降低的证据,这可能与传播或获得的 CTL 逃逸突变或传播的耐药突变有关。这些数据表明,急性感染期间的病毒动力学对 HIV 疾病结局有重大影响。